High-Potency Cannabis Use Associated With Higher Risk for Psychosis
Researchers investigated whether high-potency cannabis may be associated with a higher risk of psychosis and cannabis use disorder compared with lower-potency products.
Researchers investigated whether high-potency cannabis may be associated with a higher risk of psychosis and cannabis use disorder compared with lower-potency products.
A group of researchers explored whether individuals who experienced ongoing discrimination had a higher risk for depression.
A group of researchers in launched a clinical trial to assess whether a short stint of in-hospital counseling would have an impact on tobacco and alcohol consumption.
The Eating Recovery Center, a national, multisite treatment facility for patients with eating disorders, outlines strategies for using family-based treatment practices with adolescents who are receiving inpatient care for an eating disorder.
The researchers conducted secondary analysis of a multi-site CET trial using 86 individuals recently diagnosed with a schizophrenia spectrum disorder.
Using a shortened Nature Relatedness Scale, the Short Warwick-Edinburgh Mental Well-Being Scale (SWEMWBS), and sociodemographic information, the researchers surveyed 386 individuals aged 18 to 65 about their feelings of connection to nature and mental well-being.
Researchers used data from a European sample of teens from the IMAGEN Consortium study, which measured resting-state fMRI activity at age 14, 16, and 18.
Compared with its use for chronic pain, reliable evidence to support the use of cannabis to treat anxiety is lacking and available data are “conflicting.” To bring clarity to the issue, researchers conducted a retrospective database study of Canadian medical cannabis patients.
The researchers evaluated socioeconomic data from the 2011 Combining Medications to Enhance Depression Outcomes (CO-MED) study to ascertain whether social determinants affect treatment response in those with major depression.
Virtual reality has been explored as an adjunct to cognitive behavioral therapy, but little is known about how well it delivers automated therapy. To find out, the researchers conducted a clinical trial using 9 National Health Service trusts in England.